1. Poirier P, Giles T, Bray G et al. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effects of Weight Loss . An update of thr 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898–918.
2. Kurukulasuriya LR, Stas S, Lastra G et al. Hypertension in Obesity. Endocrinol Metab Clin N Am 2008; 37: 647–62.
3. Bramlage P, Pittrow D, Wittchen H-U et al. Hypertension in Overweight and Obese Primary Care Patients Is Highly Prevalent and Poorly Controlled: Am J Hypertens 2004; 17: 904–10.
4. Stamler R, Stamler J,Riedlinger WF, Roberts RH, Weight and blood pressure : findings in hypertension screening of 1 million Americans. JAMA 1978; 240: 1607–10.
5. Gorzelniak K, Engeli S, Janke J et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002; 20: 965–73.
6. Paul M, Mehr A P, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747–803.
7. Achard V, Boullu-Ciocca S, Desbriere R et al. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 2007; 299: 274–82.
8. Karlsson C, Lindell K, Ottosson M. Human adipose tissue expresses Angiotensinogen and enzymes required for its conversion to Angiotensin II. J Clin Endocrinol Metab 1998; 83: 3925–9.
9. Alpert MA. Obesity cardiomyopathy; pathophysiology and the evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225–36.
10. Kasper EK, Hruban H R, Baughman K L. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 1992; 70: 921–4.
11. Danser AHJ, Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005; 46: 1069–76.
12. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417–27.
13. Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforminggrowth factor-betalandmatrixproteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105–13.
14. Sakoda M, Ichihara A, Kaneshiro Y et al. (Pro)renin receptor-mediated activation of mitogenactivated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30: 1139–46.
15. Nguen G, DanserAHJ. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008; 93(Pt.5): 557–63.
16. Ichihara A, Suzuki F, Nakagawa T et al Prorenin receptor blockade inhibitsdevelopment of glomerulosclerosis in diabetic angiotensin II type la receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950–61.
17. Prescott MF et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorothiazide in patients with extreme obesity and hypertension. J Am Coll Cardiol 2007; 49(Suppl A): 370A P-1014–169.
18. Uresin Y et al. Aliskiren monotherapy lowers blood pressure more effectively than ramipril monotherapy in patients with diabetes and grade 2 hypertension: subgroup analysis of an 8-week, double-blind trial. J Hypertens 2008; 26(suppl 1): S479. Abstract PS33/THU/62.
19. Neves MF, Schiffrin EL. Aldosterone: A risk factor for vascular diseases. Cur Hypertens Rep 2003; 5: 59–65.
20. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Internat Med Res 2001; 29: 13–21.
21. Hameedi A, Shadow H L. The promise of selective aldosterone receptor antagonists for the treatment of Hypertension and Chronic Heart Failure. Cur Hypertens Rep 2000; 2: 378-83.
22. Thoenes M, Reil J-C, Khan B V et al. Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vascular Health and Risk Management 2009; 5: 577–85.
23. Dietz R, Dechend R, Yu C-M et al. Effects of the direct renin inhibitor Aliskiren and atenolol alone or in combination in patients with hypertension. J PAAC 2008; 9(3): 163–75.
24. Yarows SA, Oparil S, Patel S et al. Aliskiren in combination with valsartan lowers blood pressure more ffectively than either agent alone in patients with stage 2 hypertension: subgroup analysis of an 8-week double-blind study. Hypertension 2008; 52(4): e97 P208.
25. Calhoun D, Villamil A, Chrysant SG et al. Antihypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combination in patients with stage 2 hypertension: subgroup analysis of a randomized, double-blind, factorial trial. Hypertension 2008; 52(4): e97 P209.
26. Littlejohn TW, Trenkwalder P, Hollanders G et al. Long-term safety, tolerability and efficacy of combination therapy with Aliskiren and amlodipine in patients with hypertension 2009; 25-4: 951–9.
27. Persson F, Rossing P, Reinhard H et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomized crossover trial. Diabetologia 2010; 58(8): 1576–8.
28. Fisher ND, Danser J, Nussberger J et al. Renal and Hormonal Responses to Direct Renin Inhibition with Aliskiren in Healthy Humans. Circulation 2008; 117: 3199–205.
29. Lansang CM, Osei SY, Price DA et al. Renal hemodynamic and hormonal responses to the Angiotensin II antagonist Candesartan. Hypertension 2000; 36: 834–8.
30. Fisher ND, Allan D, Kifor I. et al. Responses to converting enzyme and renin inhibition, role of angiotensin II in humans. Hypertension 1994; 23: 44–51.
31. Splenser A, Fisher ND, Danser J, Hollenberg NK. Renal plasma flow: glomerular filtration rate relationships in men during direct renin inhibition with aliskiren. J Am Soc Hypertens 2009; 3(5): 315–20.
32. Das P, Poddar BP. Reduction of diabetic proteinuria by RAAS blockade: How fast and how long (Aliskiren vs Telmisartan).World Congress of Nephrology materials 2009, Su 260, publication online.www.wcn2009.org/accepted abstracts
33. Persson F, Rossing P, Reinhart H et al. Renoprotective effects of direct renin inhibition compared to and in combination with maximum recommended dose of Irbesartan in patients with type 2 diabetes and albuminuria. Diabetologia 2008; 51(Suppl 1): S492.
34. Andersen K, Weinberger MH, Constance CM et al. Aliskiren-based therapy provides long-term antiproteinuric effects in patients with hypertension and proteinuria: subgroup analysis of a 6-month, randomized, double-blind trial. J Am Soc Nephrology 2008; 19: SA–PO2246.
35. Parving H-H, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.

И.Е. Чазова